We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

64 hedge funds and large institutions have $342M invested in Avadel Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

23% more funds holding

Funds holding: 52 → 64 (+12)

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

15% more capital invested

Capital invested by funds: $299M → $342M (+$43.6M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

71% less call options, than puts

Call options by funds: $1.07M | Put options by funds: $3.63M

Holders
64
Holders Change
+12
Holders Change %
+23.08%
% of All Funds
1.84%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
20
Increased
19
Reduced
16
Closed
8
Calls
$1.07M
Puts
$3.63M
Net Calls
-$2.56M
Net Calls Change
-$2.66M

Top Buyers

Rank Fund Capital Flow
1
CCP
Clough Capital Partners
Massachusetts
+$10.7M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$6.96M
3
CLM
ClearBridge LLC (Maryland)
Maryland
+$4.37M
4
TI
Turner Investments
Pennsylvania
+$3.43M
5
KCM
Kennedy Capital Management
Missouri
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$8.2M
2
Millennium Management
Millennium Management
New York
-$5.72M
3
CCM
Consonance Capital Management
New York
-$5.03M
4
GTC
Ghost Tree Capital
New York
-$2.71M
5
WC
Wexford Capital
Florida
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
IMS
26
Index Management Solutions
Pennsylvania
$1.15M +$926K +76,781 New
GTC
27
Ghost Tree Capital
New York
$1.13M -$2.71M -225,000 -75%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$1.09M +$199K +16,536 +30%
IAM
29
Iridian Asset Management
Connecticut
$897K -$521K -43,200 -42%
ACM
30
Atika Capital Management
New York
$855K +$688K +57,000 New
U
31
UBS
Switzerland
$824K -$190K -15,779 -22%
TSW
32
Thompson Siegel & Walmsley
Virginia
$776K +$474K +39,300 +317%
BCM
33
Bourgeon Capital Management
Connecticut
$523K +$57.3K +4,749 +16%
EVM
34
Eaton Vance Management
Massachusetts
$521K – – –
LCG
35
Lisanti Capital Growth
New York
$515K +$414K +34,345 New
ICAP
36
Independence Capital Asset Partners
Colorado
$446K +$359K +29,750 New
DADC
37
D.A. Davidson & Co
Montana
$420K +$24.1K +2,000 +8%
Stifel Financial
38
Stifel Financial
Missouri
$390K +$121K +10,000 +63%
Janney Montgomery Scott
39
Janney Montgomery Scott
Pennsylvania
$375K +$109K +9,000 +56%
GACM
40
Green Arrow Capital Management
New York
$375K +$302K +25,000 New
IHM
41
Iguana Healthcare Management
New York
$375K +$302K +25,000 New
Credit Agricole
42
Credit Agricole
France
$323K +$260K +21,556 New
Jane Street
43
Jane Street
New York
$278K +$223K +18,523 New
Northern Trust
44
Northern Trust
Illinois
$260K +$209K +17,308 New
AC
45
Ascend Capital
California
$219K -$54.9K -4,551 -24%
CS
46
Credit Suisse
Switzerland
$217K +$174K +14,444 New
CCM
47
Condor Capital Management
New Jersey
$189K -$68.6K -5,689 -31%
US Bancorp
48
US Bancorp
Minnesota
$188K – – –
COPPSERS
49
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$173K +$139K +11,505 New
KIA
50
Kopp Investment Advisors
Minnesota
$166K +$133K +11,034 New
1
2
3

AVDL Hedge Fund Activity: Q2 2014 in Review

64 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2014, worth a combined $342M — up 15% from $299M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AVDL positions and 8 closed out — a net gain of 12 holders — while 19 added to existing stakes and 16 trimmed.

The largest buyer was Clough Capital Partners, opening a new position worth an estimated $10.7M. The largest seller was Jennison Associates, cutting an estimated $8.2M.

  • 64 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2014, up from 52 in Q1 2014.
  • Funds reported $342M of Avadel Pharmaceuticals stock for Q2 2014, up 15% quarter-over-quarter.
  • 20 funds opened new Avadel Pharmaceuticals positions in Q2 2014 and 8 closed out, a net change of +12 holders.
  • The largest Avadel Pharmaceuticals buyer in Q2 2014 was Clough Capital Partners, an estimated $10.7M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2014 was Jennison Associates, an estimated $8.2M sold.

Based on aggregated 13F filings for Q2 2014.